Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 11/17/25 → 11/17/27 |
Funding
- Genprex Incorporated: $30,550.00
25-LUN-146-GPX-PMC(ONC-003): A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed
- Hao, Zhonglin (PI)